Re-emergence of T lymphocyte-mediated synaptopathy in progressive multiple sclerosis

Front Immunol. 2024 Jun 7:15:1416133. doi: 10.3389/fimmu.2024.1416133. eCollection 2024.

Abstract

Background: Secondary progressive multiple sclerosis (SPMS) is defined by the irreversible accumulation of disability following a relapsing-remitting MS (RRMS) course. Despite treatments advances, a reliable tool able to capture the transition from RRMS to SPMS is lacking. A T cell chimeric MS model demonstrated that T cells derived from relapsing patients exacerbate excitatory transmission of central neurons, a synaptotoxic event absent during remitting stages. We hypothesized the re-emergence of T cell synaptotoxicity during SPMS and investigated the synaptoprotective effects of siponimod, a sphingosine 1-phosphate receptor (S1PR) modulator, known to reduce grey matter damage in SPMS patients.

Methods: Data from healthy controls (HC), SPMS patients, and siponimod-treated SPMS patients were collected. Chimeric experiments were performed incubating human T cells on murine cortico-striatal slices, and recording spontaneous glutamatergic activity from striatal neurons. Homologous chimeric experiments were executed incubating EAE mice T cells with siponimod and specific S1PR agonists or antagonists to identify the receptor involved in siponimod-mediated synaptic recovery.

Results: SPMS patient-derived T cells significantly increased the striatal excitatory synaptic transmission (n=40 synapses) compared to HC T cells (n=55 synapses), mimicking the glutamatergic alterations observed in active RRMS-T cells. Siponimod treatment rescued SPMS T cells synaptotoxicity (n=51 synapses). Homologous chimeric experiments highlighted S1P5R involvement in the siponimod's protective effects.

Conclusion: Transition from RRMS to SPMS involves the reappearance of T cell-mediated synaptotoxicity. Siponimod counteracts T cell-induced excitotoxicity, emphasizing the significance of inflammatory synaptopathy in progressive MS and its potential as a promising pharmacological target.

Keywords: lymphocyte-mediated synaptopathy; neurodegeneration; neuroinflammation; secondary progressive multiple sclerosis; sphingosine receptor modulators.

MeSH terms

  • Adult
  • Animals
  • Azetidines* / pharmacology
  • Azetidines* / therapeutic use
  • Benzyl Compounds* / pharmacology
  • Benzyl Compounds* / therapeutic use
  • Encephalomyelitis, Autoimmune, Experimental / drug therapy
  • Encephalomyelitis, Autoimmune, Experimental / immunology
  • Female
  • Humans
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Middle Aged
  • Multiple Sclerosis, Chronic Progressive* / drug therapy
  • Multiple Sclerosis, Chronic Progressive* / immunology
  • Neurons / metabolism
  • Neurons / pathology
  • Sphingosine 1 Phosphate Receptor Modulators / pharmacology
  • Sphingosine 1 Phosphate Receptor Modulators / therapeutic use
  • Sphingosine-1-Phosphate Receptors / metabolism
  • Synapses* / metabolism
  • Synaptic Transmission / drug effects
  • T-Lymphocytes* / drug effects
  • T-Lymphocytes* / immunology
  • T-Lymphocytes* / metabolism

Substances

  • siponimod
  • Azetidines
  • Benzyl Compounds
  • Sphingosine 1 Phosphate Receptor Modulators
  • Sphingosine-1-Phosphate Receptors

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The study was supported by: Novartis Pharma grant to DC; FISM-Fondazione Italiana Sclerosi Multipla and cofinanced with the 5 per mille public funding (cod. 2019/S/1 to DC; cod. 2020/R-Multi/018 to MSB; research fellowship 2020/BS/003 to FV); Italian Ministry of Health (RF 2021-12373319 to GM; GR-2018-12366154 to AG e FB; Ricerca Corrente to IRCCS Neuromed to DC; Ricerca Corrente to IRCCS San Raffaele Roma to GM); CNR FOE 2020-2021 project ‘Nuovi Biomarker Diagnostici e Terapeutici delle Malattie Neurodegenerative’ to GM and DC; Work supported by #NEXTGENERATIONEU (NGEU) and funded by the Ministry of University and Research (MUR), National Recovery and Resilience Plan (NRRP), project MNESYS (PE0000006) to DC and GM and AM; Private donations in memory of Veronica Tozzi to DC.